Research Progress of Anti-Ebola Virus Antibodies
Posted by Jerry Carter on August 26th, 2019
Targeting at this headache bothering the WHO and people in South Africa, Creative Biolabs, as one of the top antibody suppliers provides various types of recombinant Ebolavirus antibody products to facilitate the Microbiology research, which can bring hopes to the drug and vaccine manufacturing.
1. Ebola Haemorrhagic Fever
Ebola hemorrhagic fever (Ebola) is a serious disease of hemorrhagic fever whose pathogen is Ebola virus that is named after its discovery in the Ebola River region of Africa. Since the first Ebola haemorrhagic fever outbreak was reported in 1976, there have been several other times in 2014, with a fatality rate of up to 90%. Among them, the outbreak in West Africa in 2014-2016 was the most serious, with 29,000 infected patients and 11,000 deaths. That was mainly caused by Zaire Ebola virus and spread to Guinea, Libya, Sierra Leone and other West African countries, causing global panic. The original host of Ebola virus is generally considered to be fruit bats. In addition, chimpanzees, gorillas, rhesus monkeys and other animals may also transmit Ebola virus. Viruses can be transmitted by contacting with body fluids, skin or nasal secretions of patients.
2. Overview of Ebola Virus
Ebola virus is a filoviridae virus. It is an RNA virus with a capsule, a single negative chain and no segments. The full length of the gene is about 19 kb. Its diameter is about 80 nm, and its length is about 1000 nm. Ebola virus has many shapes, such as branching and ring, which consists of a nuclear capsid and a capsule with long protuberances.
Ebola virus can be divided into five subtypes, including Zaire Ebola virus (ZEBOV), Sudan Ebola virus (SEBOV), TaForest ebolavirus (TAFV), Bundibugyoe ebolavirus (BDBV) and Reston ebolavirus (RESTV). The virulence and pathogenic process of different subtypes are different. The other four subtypes except Leston type are all pathogenic to human beings, and Zaire type is the most pathogenic, with a mortality rate of 90%.
The genome of Ebola virus mainly encodes seven structural proteins, including envelope glycoprotein GP, nucleocapsid protein NP, RNA polymerase L and matrix protein VP (including VP30, VP24, VP35 and VP40). GP protein is closely related to viral binding receptors, cell entry and other processes. After the N-terminal signal peptide is decomposed after translation, GP protein produces two subunits GP1 and GP2, which form dimers in the form of disulfide bonds. Studies have shown that GP protein is closely related to major pathological manifestations such as vascular injury and abnormal coagulation function caused by EBOV infection. Therefore, GP can be used as an important target for the development of anti-Ebola drugs.
Due to the fact that discriminating EVD from malaria, typhoid fever, meningitis and other infectious diseases is relatively difficult, scientists have developed a series of methods to be adopted, to which the multifarious products from Creative Biolabs can be applicable, including Enzyme-linked Immunosorbent Assay (ELISA), Immunocytochemistry, Immunofluorescence, etc. The provided abundant recombinant Sudan ebolavirus antibodies target at the L (an RNA-dependent RNA polymerase and a component of viral polymerase complex) and GP (toxic protein) of EBOV, of which the peptide sequences correspond to the important amio acid residues like TRSFTTHFL, MSDIFHALV, GFKLRSAVM, and TTLPSQNST, etc.
Up to now, there is no approval treatment for Ebola virus disease. Existing EBOV vaccines include DNA vaccine, recombinant subunit vaccine, virus-like particle vaccine and virus vector vaccine. Creative Biolabs is concentrating on facilitating the medical researchers or drug industry to develop various possible treatments, like blood products, immunotherapy and drug therapy that are currently being evaluated.
“We hope to help the research and development of EBOV drugs or therapies,” said the Head of Creative Biolabs. The serious disease has attacked Africa many times, and all the medical workers are working on the whole-hearted study of effective treatment. As a piloting distributor in the area of recombinant Ebolavirus antibody, Creative Biolabs is certainly contributing under the support of experienced scientists. More details about the Ebola virus antibodies are available at https://www.antibody-creativebiolabs.com/.
About Creative Biolabs
Since 2004, Creative Biolabs started working on offering high-quality services in academic and life science worldwide. As the leading role in discovering and manufacturing recombinant antibodies, advanced antibody research tools, professional technical support, and rapid global delivery are utilized to ensure quality for scientific research workers and customers in industry. A custom-service-centered business model is taken seriously for optimizing the drug development process, leveraging accessible resources, and gathering a team from various backgrounds to conduct drug discovery projects in the future.
Like it? Share it!
About the AuthorJerry Carter
Joined: June 15th, 2019
Articles Posted: 52
More by this author